XBIO 10-Q filed 2026-11-12 | Key takeaways
XBIO filed its 10-Q; the most relevant disclosure change is added Business combinations: Xenetic entered into a Share Exchange Agreement on September 14, 2026 to acquire Santersus AG, a Swiss biotech company focused on NET-targeting technologies, with Santersus shareholders expected to own approximately 85% of the combined company post-closing and. Customer concentration: Takeda Pharmaceutical Co. Ltd. represented 100% of revenue.
Read source-backed brief